MDNews - Mid Penn

Innovation Edition 2016

Issue link: https://viewer.e-digitaledition.com/i/751011

Contents of this Issue

Navigation

Page 9 of 23

COOPERATION, INNOVATION AND A PASSION FOR SAVING YOUNG LIVES ARE THE DRIVING FORCES BEHIND THE PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS PROGRAM AT PENN STATE CHILDREN'S HOSPITAL. Four Diamonds: Courage, Wisdom, Honesty, Strength The care of children enrolled in studies through the Pediatric Oncology Experimental Therapeutics Program at Penn State Children's Hospital receives crucial financial support from Four Diamonds. This fund was created in memory of Christopher Millard, who lost his life to cancer in 1972, but whose legacy lives on in innovative research conducted with the help of Four Diamonds. Bringing Hope to Young Cancer Patients and Their Families BY VALERIE LAUER EACH YEAR, MORE than 15,000 children and adolescents are diagnosed with cancer. Despite advances that have markedly increased survivorship the past several decades, one in five of these children does not survive five years after diagnosis. "For patients who are not responsive to conventional treatment or who face recur r i ng disea se, t he prog nosis is challenging," says Valerie Brown, MD, PhD, clinical director of experimental therapeutics of the Division of Pediatric Hematolog y-Oncolog y at Penn State Health Milton S. Hershey Medial Center and Penn State Children's Hospital. "To truly help them, we need to do more than rearrange the deck chairs on the Titanic. We need to build a better boat. That's what our Pediatric Oncology Experimental Therapeutics Program is doing." EVIDENCE-BASED HOPE The Pediatric Oncology Experimental Therapeutics Program helps establish the safety and e¨cacy of pediatric cancer treatment protocols. By connecting patients to national clinical trials, the hospital provides local access to the most advanced treatments available. "At any given time, we have dozens of research trials open to accommodate a large spectrum of patients," Dr. Brown says. "There are five for neuroblastoma alone. Once we had a patient who came to enroll in a neuroblastoma trial for preventing relapse, only to discover her cancer had come back. However, I didn't have to go to the family empty-handed. There were three other studies she qualified for. That's the power of a program like ours. We have options for families — hope when they feel things are hopeless." Ongoing pediatric cancer research in the program includes, among other lines of investigation, work on relapsed or refractory acute myeloid leukemia, hepatoblastoma, refractory solid tumors, medulloblastoma, and ependymoma. CONNECTED TO AN EXPERT NETWORK A s pa r t of Hershey Medica l Center, the Pediatric Oncolog y Experimental Therapeutics Program is linked to leading providers in a variety of fields, including imaging and oncology care. Ready access to ancillary services improves the patient experience and reduces stress. Dr. Brow n a nd her collea g ues a lso work in a sha red ca re model, forg ing c o l l a b o r a t i v e r e l a t i o n s h i p s w i t h r e f e r r i n g p h y s i c i a n s f o r o p t i m a l patient service. They use a similar team approach to ma ke the clinica l tria ls process as comfortable and convenient as possible. If another institution with which the program has partnered on a Pediatric Oncology Experimental Therapeutics at Penn State Children's Hospital: clinica l tr ia l is closer to a potentia l participant's home, the family is advised of that option, Dr. Brown notes. That can spare patients and families the burden and expense of travel. "Together, we are making a real di›erence in the standard of care for hard-to-treat pediatric cancers and other conditions," Dr. Brown says. ■ National Research, Community Setting THE PEDIATRIC ONCOLOGY E X PERIMENTA L THER A PEUTIC S PROGR A M is a member of the following national consortia, collaborations that allow Penn State Children's Hospital to offer a broad range of clinical trials and advanced treatments: + Children's Oncology Group + Neuroblastoma and Medulloblastoma Translational Research Consortium + Pediatric Blood and Marrow Transplant Consortium + Pediatric Oncology Experimental Therapeutics Investigators' Consortium 1 0 1 0❱❱❱❱❱ P E D I A T R I C O N C O L O G Y

Articles in this issue

Archives of this issue

view archives of MDNews - Mid Penn - Innovation Edition 2016